Cargando…

Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells

SIMPLE SUMMARY: CDK4/6 inhibitors (CDKis) are a first-line treatment for metastatic hormone-receptor-positive breast cancer, but resistance frequently develops. One potential resistance mechanism could be induction of cellular senescence in non-tumor tissues. The aim of our study was to identify CDK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gallanis, Gregory T., Sharif, Ghada M., Schmidt, Marcel O., Friedland, Benjamin N., Battina, Rohith, Rahhal, Raneen, Davis, John E., Khan, Irfan S., Wellstein, Anton, Riegel, Anna T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046966/ https://www.ncbi.nlm.nih.gov/pubmed/36980794 http://dx.doi.org/10.3390/cancers15061908

Ejemplares similares

321 Impact of CDK4/6 inhibitor-induced cellular senescence on stromal responses to breast cancer
por: Gallanis, Gregory T., et al.
Publicado: (2022)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
por: Pogacar, Ziva, et al.
Publicado: (2022)

Subpopulations of AIB1 isoform-expressing breast cancer cells enable invasion and metastasis
por: Kiliti, Amber J., et al.
Publicado: (2023)

AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer
por: Kiliti, Amber J., et al.
Publicado: (2023)

Low Dose Chronic Angiotensin II Induces Selective Senescence of Kidney Endothelial Cells
por: Khan, Irfan, et al.
Publicado: (2021)

Pleiotrophin (PTN) Expression and Function and in the Mouse Mammary Gland and Mammary Epithelial Cells
por: Rosenfield, Sonia M., et al.
Publicado: (2012)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Correction: Pleiotrophin (PTN) Expression and Function in the Mouse Mammary Gland and Mammary Epithelial Cells
por: Rosenfield, Sonia M., et al.
Publicado: (2013)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer
por: Wang, Xianzhe, et al.
Publicado: (2023)

Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling
por: Sharif, Ghada M, et al.
Publicado: (2015)

Emerging roles of histone modifications and HDACs in RNA splicing
por: Rahhal, Raneen, et al.
Publicado: (2019)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Impaired CXCL12 signaling contributes to resistance of pancreatic cancer subpopulations to T cell-mediated cytotoxicity
por: Lin, Yuan-Na, et al.
Publicado: (2022)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion
por: Berens, Eric B., et al.
Publicado: (2016)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)

Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy
por: Cayo, Angel, et al.
Publicado: (2023)

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib
por: Böhm, Michael J., et al.
Publicado: (2019)

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
por: Hsieh, Feng‐Shu, et al.
Publicado: (2017)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch pathway
por: Bi, Hengtai, et al.
Publicado: (2021)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023)

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
por: Miettinen, Teemu P, et al.
Publicado: (2018)

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
por: Pennycook, Betheney R., et al.
Publicado: (2021)

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022)

Use of differential scanning fluorimetry as a high-throughput assay to identify nuclear receptor ligands
por: DeSantis, Kara, et al.
Publicado: (2012)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

Conditionally Reprogrammed Normal and Transformed Mouse Mammary Epithelial Cells Display a Progenitor-Cell–Like Phenotype
por: Saenz, Francisco R., et al.
Publicado: (2014)

Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
por: Jost, Tina, et al.
Publicado: (2021)

The metastatic niche and stromal progression
por: Sleeman, Jonathan P.
Publicado: (2012)

Establishment of In Vitro Models by Stress-Induced Premature Senescence for Characterizing the Stromal Vascular Niche in Human Adipose Tissue
por: Wahlmueller, Marlene, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i4k7m16smenb3fmmr7vv5udg69